This review summarizes novel drug formulations to improve outcomes in spinal cord injury, suggesting new therapeutic strategies.
Spinal cord injury (SCI) is a devastating condition associated with high rates of disability and mortality, as well as a significant financial burden. The current clinical interventions have limited therapeutic effectiveness, primarily due to relentless secondary injury cascades and the inherent challenge of neuronal circuit regeneration. Advances in biomaterials and fabrication technologies have led to the emergence of various novel formulations designed to specifically address these challenges and serve as a high-tech arsenal for researchers. This review delineates the pathophysiological mechanisms underlying SCI and the development of its self-propagating injury cascade. It also provides a comprehensive summary of recent advancements in the development and application of novel drug formulations, highlighting their distinct advantages in interrupting the injury cascade. This review aims to foster the development of more effective therapeutic strategies and ultimately improve therapeutic outcomes for patients with SCI.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: